These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522 [TBL] [Abstract][Full Text] [Related]
26. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186 [TBL] [Abstract][Full Text] [Related]
27. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
28. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M J Transl Med; 2018 Apr; 16(1):87. PubMed ID: 29615063 [TBL] [Abstract][Full Text] [Related]
30. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727 [TBL] [Abstract][Full Text] [Related]
31. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462 [TBL] [Abstract][Full Text] [Related]
32. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901 [No Abstract] [Full Text] [Related]
33. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231 [TBL] [Abstract][Full Text] [Related]
34. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Remon J; Chaput N; Planchard D Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384 [TBL] [Abstract][Full Text] [Related]
35. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982 [TBL] [Abstract][Full Text] [Related]
36. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918 [TBL] [Abstract][Full Text] [Related]
37. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382 [TBL] [Abstract][Full Text] [Related]
39. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496 [TBL] [Abstract][Full Text] [Related]
40. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]